

# CITATION REPORT

List of articles citing

**Clinical pharmacology of buprenorphine: ceiling effects at high doses**

**DOI: 10.1038/clpt.1994.71**

**Clinical Pharmacology and Therapeutics, 1994, 55, 569-80.**

**Source:** <https://exaly.com/paper-pdf/25193552/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
615	Effects of buprenorphine and methadone in methadone-maintained subjects. <b>1995</b> , 119, 268-76		103
614	Sustained oral mucosal delivery in human volunteers of buprenorphine from a thin non-eroding mucoadhesive polymeric disk. <b>1995</b> , 34, 243-250		19
613	A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. <b>1995</b> , 40, 17-25		156
612	Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. <b>1995</b> , 40, 27-35		81
611	Buprenorphine as a Pharmacotherapy for Opiate Addiction: What Dose Provides a Therapeutic Response?. <b>1996</b> , 5, 220-230		2
610	A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. <b>1996</b> , 22, 523-31		40
609	The Effects of Transnasal Butorphanol on Mood and Psychomotor Functioning in Healthy Volunteers. <b>1996</b> , 82, 931-935		1
608	Pharmacokinetic evaluation of transdermal buprenorphine in man. <b>1996</b> , 132, 81-87		9
607	Prenatal administration of buprenorphine in the rat: effects on the rest-activity cycle at 22 and 30 days of age. <b>1996</b> , 55, 607-13		17
606	Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. <b>1996</b> , 20, 369-78		203
605	The effects of transnasal butorphanol on mood and psychomotor functioning in healthy volunteers. <b>1996</b> , 82, 931-5		6
604	Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. <b>1997</b> , 54, 713-20		244
603	Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. <b>1997</b> , 33, 344-400		63
602	The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient setting. <b>1997</b> , 2, 191-200		21
601	Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. <b>1997</b> , 45, 81-91		33
600	The effects of buprenorphine in buprenorphine-maintained volunteers. <b>1997</b> , 129, 329-38		47
599	Discriminative stimulus effects of buprenorphine in the rat. <b>1997</b> , 130, 292-9		15

598	Interactions of buprenorphine and selective dopamine receptor antagonists in the rat nucleus accumbens. <b>1998</b> , 31, 425-9		6
597	Buprenorphine alters ethanol self-administration in rats: dose-response and time-dependent effects. <b>1998</b> , 140, 29-37		11
596	Determination of buprenorphine in plasma by liquid chromatography: application to heroin-dependent subjects. <b>1998</b> , 16, 1295-300		18
595	[Conventional techniques for analgesia: opioids and non-opioids. Indications, adverse effects and monitoring]. <b>1998</b> , 17, 573-84		3
594	A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. <b>1998</b> , 105, 100-5		153
593	Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. <b>1998</b> , 22, 430-4		172
592	Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study. <b>1998</b> , 4 Suppl 1, 13-8		61
591	A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 66, 306-14	6.1	23
590	Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. <b>1999</b> , 145, 162-74		56
589	Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. <b>1999</b> , 56, 55-60		66
588	Opioid reinforcement in heroin-dependent volunteers during outpatient buprenorphine maintenance. <b>1999</b> , 56, 191-203		34
587	Opiate drugs: 'guilt by association'. <b>2000</b> , 5, 122-3		6
586	Clinical issues in using buprenorphine in the treatment of opiate dependence. <b>2000</b> , 19, 329-335		7
585	Buprenorphine and naloxone for heroin dependence. <b>2000</b> , 2, 519-26		45
584	Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. <b>2000</b> , 148, 374-83		74
583	Pharmacologic treatment of heroin-dependent patients. <b>2000</b> , 133, 40-54		117
582	Thrice-weekly versus daily buprenorphine maintenance. <b>2000</b> , 47, 1072-9		46
581	Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. <b>2000</b> , 60, 39-50		114

580	Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. <b>2000</b> , 58, 143-52	100
579	A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. <b>2000</b> , 59, 223-33	32
578	Effect of buprenorphine on CYP3A activity in rat and human liver microsomes. <b>2000</b> , 66, 1293-8	33
577	Addiction pharmacotherapy 2000: new options, new challenges. <b>2000</b> , 32, 371-8	33
576	Hepatitis after intravenous buprenorphine misuse in heroin addicts. <b>2001</b> , 34, 346-50	68
575	Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. <b>2001</b> , 34, 261-9	81
574	Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. <b>2001</b> , 61, 173-81	53
573	Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days. <b>2001</b> , 64, 111-6	15
572	Practice-based buprenorphine maintenance treatment (BMT): how do French healthcare providers manage the opiate-addicted patients?. <b>2001</b> , 21, 135-44	31
571	Rapid heroin detoxification using a single high dose of buprenorphine. <b>2001</b> , 33, 191-3	18
570	Office-based treatment for opioid dependence: reaching new patient populations. <b>2001</b> , 158, 1200-4	39
569	Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. <b>2001</b> , 154, 28-37	60
568	Deaths involving buprenorphine: a compendium of French cases. <b>2001</b> , 121, 65-9	189
567	New trends in opiate pharmacotherapy. <b>2001</b> , 20, 79-94	10
566	Gradual dose taper following chronic buprenorphine. <b>2001</b> , 10, 111-21	17
565	Safety and tolerability of opioid analgesia: a comparable class profile?. <b>2001</b> , 8, 103-111	
564	Buprenorphine substitution ameliorates spontaneous withdrawal in fentanyl-dependent rat pups. <b>2001</b> , 49, 50-5	9
563	Transplacental transfer and metabolism of buprenorphine. <b>2002</b> , 300, 26-33	116

562	Intravenous buprenorphine self-administration by detoxified heroin abusers. <b>2002</b> , 301, 266-76	37
561	Treatment of heroin dependence with buprenorphine in primary care. <b>2002</b> , 28, 231-41	75
560	Der Einsatz von Buprenorphin in der stationären Entzugsbehandlung. <b>2002</b> , 3, 205-210	1
559	Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. <b>2002</b> , 303, 695-703	72
558	Toxicologic aspects of heroin substitution treatment. <b>2002</b> , 24, 193-8	21
557	Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. <b>2002</b> , 41, 661-80	194
556	Treatment of heroin (diamorphine) addiction: current approaches and future prospects. <b>2002</b> , 62, 1331-43	39
555	Heroin detoxification with buprenorphine on an inpatient psychiatric unit. <b>2002</b> , 23, 163-9	13
554	Buprenorphine: blending practice and research. <b>2002</b> , 23, 87-92	49
553	Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. <b>2002</b> , 65, 283-90	143
552	Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. <b>2002</b> , 160, 344-52	45
551	Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. <b>2002</b> , 161, 1-16	54
550	A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. <b>2002</b> , 97, 533-42	53
549	Trends in opiate and opioid poisonings in addicts in north-east Paris and suburbs, 1995-99. <b>2002</b> , 97, 1295-304	33
548	A preliminary investigation comparing pre-operative morphine and buprenorphine for postoperative analgesia and sedation in cats. <b>2002</b> , 29, 29-35	49
547	A new series of 13 buprenorphine-related deaths. <b>2002</b> , 35, 513-6	89
546	Buprenorphine dosing regime in the management of out-patient heroin withdrawal. <b>2002</b> , 21, 39-45	16
545	Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine tablets. <b>2003</b> , 22, 359-61	13

544	[Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain]. <b>2003</b> , 153, 317-22	23
543	Transdermal buprenorphine. <b>2003</b> , 63, 1999-2010; discussion 2011-2	101
542	Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. <b>2003</b> , 69, 317-22	20
541	Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection. <b>2003</b> , 69, 263-72	46
540	From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. <b>2003</b> , 70, S3-11	109
539	The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. <b>2003</b> , 70, S13-27	147
538	Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?. <b>2003</b> , 70, S29-37	78
537	Pharmacokinetics of the combination tablet of buprenorphine and naloxone. <b>2003</b> , 70, S39-47	137
536	Buprenorphine: how to use it right. <b>2003</b> , 70, S59-77	187
535	Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block. <b>2003</b> , 72, 75-83	45
534	Opioid Research. <b>2003</b> ,	1
533	Old dog--new (ma)trix. <b>2003</b> , 90, 722-4	24
532	Clinical treatment of opioid addiction and dependence. <b>2003</b> , 84, 285-95	5
531	Buprenorphine for Opioid Detoxification. <b>2003</b> , 2, 107-112	7
530	A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. <b>2003</b> , 179, 38-42	71
529	Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. <b>2003</b> , 23, 10331-7	192
528	Research Note [Review of Corrections-Based Therapy for Opiate-Dependent Patients: Implications for Buprenorphine Treatment among Correctional Populations. <b>2004</b> , 34, 451-480	34
527	Office-based buprenorphine treatment for opioid-dependent patients. <b>2004</b> , 12, 321-38	34

526	Evaluation of an injection depot formulation of buprenorphine: placebo comparison. <b>2004</b> , 99, 1439-49	37
525	The clinical use of buprenorphine in opiate addiction: evidence and practice. <b>2004</b> , 16, 246-74	18
524	Buprenorphine pharmacology and clinical applications. <b>2004</b> , 23, 281-290	1
523	A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal. <b>2004</b> , 23, 171-5	9
522	A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. <b>2004</b> , 23, 311-7	36
521	Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. <b>2004</b> , 13 Suppl 1, S42-66	114
520	Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations. <b>2004</b> , 172, 58-67	25
519	Post-marketing surveillance of buprenorphine. <b>2004</b> , 13, 615-9	13
518	Medicines and the drug control treaties: is buprenorphine for opioid addiction at risk of being lost?. <b>2004</b> , 19, 215-24	3
517	The development and application of a rapid gas chromatography-mass spectrometry method to monitor buprenorphine withdrawal protocols. <b>2004</b> , 143, 121-5	29
516	Pharmacokinetic Properties of a Single Intramuscular Dose of Buprenorphine in African Grey Parrots ( <i>Psittacus erithacus erithacus</i> ). <b>2004</b> , 18, 224-228	35
515	Combating opiate dependence: a comparison among the available pharmacological options. <b>2004</b> , 5, 713-25	60
514	The development and application of a rapid gas chromatography?mass spectrometry method to monitor buprenorphine withdrawal protocols. <b>2004</b> ,	
513	Buprenorphine in the treatment of opioid dependence. <b>2004</b> , 14, 209-16	50
512	Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. <b>2004</b> , 43, 329-40	62
511	Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. <b>2004</b> , 73, 11-22	48
510	Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. <b>2004</b> , 74, 37-43	61
509	A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. <b>2004</b> , 74, 205-9	32

508	Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial. <b>2004</b> , 27, 75-82	17
507	Effects of high-dose intravenous buprenorphine in experienced opioid abusers. <b>2004</b> , 24, 479-87	32
506	Treatment of Opiate Addicts With Buprenorphine. <b>2004</b> , 3, 58-70	1
505	Acute hepatitis due to buprenorphine administration. <b>2004</b> , 16, 1033-7	43
504	Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients. <b>2005</b> , 19 Suppl 3, S221-6	18
503	Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. <b>2005</b> , 62, 1157-64	145
502	Opioid plasma concentrations in methadone-and buprenorphine-maintained patients. <b>2005</b> , 10, 365-71	5
501	Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. <b>2005</b> , 507, 87-98	116
500	Recent advances in the treatment of opiate addiction. <b>2005</b> , 5, 161-167	12
499	Clorazepate affects cell surface regulation of delta and kappa opioid receptors, thereby altering buprenorphine-induced adaptation in the rat brain. <b>2005</b> , 1063, 84-95	9
498	Medications development: successes and challenges. <b>2005</b> , 108, 94-108	131
497	Buprenorphine: considerations for pain management. <b>2005</b> , 29, 297-326	204
496	Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. <b>2005</b> , 60, 875-81	30
495	Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. <b>2005</b> , 181, 664-75	60
494	Hepatitis C treatment of substance users in pharmacotherapy for addiction. <b>2005</b> , 4, 112-119	1
493	High-dose buprenorphine: perioperative precautions and management strategies. <b>2005</b> , 33, 17-25	48
492	What every psychiatrist should know about buprenorphine in substance misuse. <b>2005</b> , 29, 225-227	5
491	11 Buprenorphine for Opioid Dependence. <b>2005</b> ,	



490 Innentitel. **2005**,

489	Abstracts of the European Association of Poisons Centres and Clinical Toxicologists XXV International Congress. <b>2005</b> , 43, 387-538	1
488	Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement. <b>2005</b> , 30, 1681-92	65
487	Transdermal buprenorphine in the treatment of chronic pain. <b>2005</b> , 5, 315-23	29
486	Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. <b>2005</b> , 41, 891-6	45
485	Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. <b>2005</b> , 41 Suppl 1, S89-95	61
484	Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. <b>2005</b> , 57, 1-26	284
483	Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. <b>2005</b> , 313, 1136-49	91
482	Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals. <b>2005</b> , 315, 1320-30	40
481	Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. <b>2005</b> , 94, 825-34	215
480	Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis. <b>2005</b> , 5, 583-91	10
479	Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. <b>2005</b> , 27, 451-62	43
478	The effect of buprenorphine and benzodiazepines on respiration in the rat. <b>2005</b> , 79, 95-101	33
477	Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. <b>2005</b> , 44, 661-80	202
476	Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. <b>2005</b> , 157, 211-9	15
475	Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences. <b>2006</b> , 25, 79-85	71
474	Risk identification, risk assessment, and risk management of abusable drug formulations. <b>2006</b> , 83 Suppl 1, S68-76	32
473	Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. <b>2006</b> , 104, 1232-42	64

472	The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. <b>2006</b> , 28, 245-51	61
471	Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. <b>2006</b> , 46, 179-92	45
470	Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. <b>2006</b> , 26, 274-83	50
469	An injection depot formulation of buprenorphine: extended bio-delivery and effects. <b>2006</b> , 101, 420-32	42
468	Liquid chromatographic-electrospray ionization mass spectrometric quantitative analysis of buprenorphine, norbuprenorphine, nordiazepam and oxazepam in rat plasma. <b>2006</b> , 41, 1135-45	13
467	[Requirements of a regional medical service for drug addicted patients]. <b>2006</b> , 156, 102-10	2
466	Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period. <b>2006</b> , 189, 297-306	18
465	Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. <b>2006</b> , 212, 256-67	51
464	Dexamethasone hepatic induction in rats subsequently treated with high dose buprenorphine does not lead to respiratory depression. <b>2006</b> , 217, 352-62	9
463	Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. <b>2006</b> , 355, 365-74	271
462	Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. <b>2006</b> , 43 Suppl 4, S224-34	67
461	Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. <b>2006</b> , 40, 392-6	49
460	Novel metabolites of buprenorphine detected in human liver microsomes and human urine. <b>2006</b> , 34, 440-8	60
459	Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine. <b>2006</b> , 318, 282-7	32
458	Rational use of sublingual opioids in palliative medicine. <b>2007</b> , 10, 465-75	34
457	Combined Behavioral and Pharmacological Treatment of Opioid-Dependent Adolescents: A Randomized, Controlled Trial. <b>2007</b> , 2, 251-264	
456	Preclinical Development and Clinical Implementation of Treatments for Substance Abuse Disorders. <b>2007</b> , 5, 151-162	1
455	Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement. <b>2007</b> , 15, 1-20	3

454	Buprenorphine: the basic pharmacology revisited. <b>2007</b> , 1, 68-72	49
453	Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosing. <b>2007</b> , 1, 88-95	7
452	Buprenorphine-naloxone Treatment for Pre-release Opioid-dependent Inmates in Puerto Rico. <b>2007</b> , 1, 126-32	45
451	Examination of the preclinical antinociceptive efficacy of buprenorphine and its designation as full- or partial-agonist. <b>2007</b> , 9, 145-152	34
450	Subjective effects of additional doses of buprenorphine in patients on buprenorphine maintenance. <b>2007</b> , 32, 320-31	8
449	Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. <b>2007</b> , 90, 261-9	72
448	Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. <b>2007</b> , 29, 2179-93	49
447	Use of Potent Opioids for Chronic Pain Management. <b>2008</b> , 317-409	
446	Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. <b>2007</b> , 33, 869-74	23
445	Sustained-release naltrexone: novel treatment for opioid dependence. <b>2007</b> , 16, 1285-94	60
444	Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. <b>2007</b> , 61, 4-12	76
443	Poor Man's Smack: A Qualitative Study of Buprenorphine Injecting in Melbourne, Australia. <b>2007</b> , 34, 525-548	2
442	Opiates and Addiction. <b>2007</b> ,	
441	Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 81, 50-8	6.1 74
440	Design and evaluation of matrix-based controlled release tablets of diclofenac sodium and chondroitin sulphate. <b>2007</b> , 8, E88	25
439	Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. <b>2007</b> , 26, 405-10	48
438	What is new in neuropathic pain?. <b>2007</b> , 15, 363-72	45
437	Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. <b>2007</b> , 44, 188-95	5

436	Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats. <b>2008</b> , 25, 183-93	48
435	Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers. <b>2008</b> , 103, 94-101	21
434	Effects of various combinations of benzodiazepines with buprenorphine on arterial blood gases in rats. <b>2008</b> , 103, 228-39	23
433	Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>2008</b> , 83, 144-52	6.1 25
432	Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). <b>2008</b> , 8, 287-313	577
431	High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study. <b>2008</b> , 8, 355-61	11
430	Exposure to opioid maintenance treatment reduces long-term mortality. <b>2008</b> , 103, 462-8	136
429	Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. <b>2008</b> , 19, 450-8	71
428	Aspectos farmacológicos de los programas de tratamiento con buprenorfina-naloxona. <b>2008</b> , 10, 1-16	2
427	Opioids and the treatment of chronic pain: controversies, current status, and future directions. <b>2008</b> , 16, 405-16	356
426	Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres. <b>2008</b> , 94, 125-32	16
425	Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. <b>2008</b> , 97, 105-13	48
424	Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?. <b>2008</b> , 22, 99-111	36
423	Knowledge about buprenorphine and methadone among those receiving treatment for opioid dependence. <b>2008</b> , 15, 395-409	11
422	Attitudes and knowledge of substance misusers regarding buprenorphine and methadone maintenance therapy. <b>2008</b> , 13, 143-153	12
421	A pilot study for a randomized controlled and patient preference trial of buprenorphine versus methadone maintenance treatment in the management of opiate dependent patients. <b>2008</b> , 13, 73-82	10
420	Transdermal buprenorphine in chronic pain: indications and clinical experience. <b>2008</b> , 1, 729-36	6
419	Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. <b>2008</b> , 122, e601-7	82

418	Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. <b>2008</b> , 300, 2003-11	256
417	Narrative review: buprenorphine for opioid-dependent patients in office practice. <b>2008</b> , 148, 662-70	38
416	Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. <b>2008</b> , 2, 103-7	16
415	Hepatitis infection in the treatment of opioid dependence and abuse. <b>2008</b> , 1, 15-61	2
414	Treatment of opioid dependence. 381-401	1
413	Management of chronic pain in the elderly: focus on transdermal buprenorphine. <b>2008</b> , 3, 421-30	67
412	Transdermal buprenorphine - a critical appraisal of its role in pain management. <b>2009</b> , 2, 117-34	31
411	Buprenorphine prescription, misuse and service provision: a global perspective. <b>2009</b> , 15, 354-363	8
410	Effect of plasma proteins on buprenorphine transfer across dually perfused placental lobule. <b>2009</b> , 22, 646-53	5
409	Opioid dependence treatment: options in pharmacotherapy. <b>2009</b> , 10, 1727-40	158
408	Buprenorphine for opioid dependence. <b>2009</b> , 9, 609-16	21
407	Opiate Receptors and Antagonists. <b>2009</b> ,	3
406	Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis. <b>2009</b> , 43, 973-7	24
405	Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. <b>2009</b> , 31, 527-41	39
404	Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test: a combination analysis study. <b>2009</b> , 605, 57-62	29
403	Buprenorphine inhibits bradykinin-induced release of calcitonin gene-related peptide from rat trigeminal neurons via both mu-opioid and nociceptin/orphanin peptide receptors. <b>2009</b> , 609, 45-50	6
402	[High-dose buprenorphine for outpatient palliative pain therapy]. <b>2009</b> , 23, 180-6	3
401	Treatment of opioid-dependent adolescents and young adults with buprenorphine. <b>2009</b> , 11, 360-3	27

- 400 Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. **2009**, 13, 219-30 165
- 399 Buprenorphine tapering schedule and illicit opioid use. **2009**, 104, 256-65 90
- 398 Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. **2009**, 28, 226-31 72
- 397 The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. **2009**, 10, 2537-44 29
- 396 Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. **2009**, 99, 222-30 156
- 395 Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. **2009**, 41, e8-e10 30
- 394 Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats. **2009**, 191, 327-40 35
- 393 Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. **2009**, 69, 577-607 96
- 392 [Mechanisms of opioid-induced overdose: experimental approach to clinical concerns]. **2009**, 67, 353-9 12
- 391 Opioids for the treatment of chronic non-cancer pain in older people. **2009**, 26 Suppl 1, 63-73 24
- 390 Spotlight on buprenorphine/naloxone in the treatment of opioid dependence. **2009**, 23, 899-902 16
- 389 Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. **2009**, 110, 36-46 22
- 388 Pilot randomised controlled trial of community pharmacy administration of buprenorphine versus methadone. **2010**, 14, 243-248 6
- 387 In-vitro and in-vivo characterization of a buprenorphine delivery system. **2006**, 58, 295-302 23
- 386 [Status quo of opioid agonist maintenance therapy in Germany]. **2010**, 53, 332-9 1
- 385 Buprenorphine-related deaths: unusual forensic situations. **2010**, 124, 647-51 19
- 384 Präklinisches Management von Drogenintoxikationen. **2010**, 13, 803-814
- 383 Methadone, buprenorphine, and street drug interactions with antiretroviral medications. **2010**, 7, 152-60 59

382	A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. <b>2010</b> , 40, 266-78	47
381	Effect of cocaine use on buprenorphine pharmacokinetics in humans. <b>2010</b> , 19, 38-46	14
380	Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir. <b>2010</b> , 19, 17-29	21
379	Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. <b>2010</b> , 19, 4-16	188
378	Lack of clinically significant drug interactions between nevirapine and buprenorphine. <b>2010</b> , 19, 30-7	20
377	Indicators of buprenorphine and methadone use and abuse: what do we know?. <b>2010</b> , 19, 73-88	29
376	(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancy. <b>2010</b> , 70, 895-902	19
375	Infant neurobehavior following prenatal exposure to methadone or buprenorphine: results from the neonatal intensive care unit network neurobehavioral scale. <b>2010</b> , 45, 2244-57	34
374	Alternativas farmacológicas para el tratamiento de la dependencia a la heroína: un nuevo reto en Colombia. <b>2010</b> , 39, 188S-212S	2
373	Buprenorphine in postoperative pain management. <b>2010</b> , 28, 601-9	28
372	A systematic review and empirical analysis of the relation between dose and duration of drug action. <b>2010</b> , 50, 17-26	6
371	Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). <b>2010</b> , 13, 905-15	99
370	Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre. <b>2010</b> , 30 Suppl 1, 27-31	5
369	Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre. <b>2010</b> , 30 Suppl 1, 13-9	7
368	Sublingual buprenorphine. <b>2010</b> , 25, 413-5	
367	Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. <b>2010</b> , 38, 403-7	40
366	The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. <b>2010</b> , 39, 340-52	87
365	Buprenorphine 5, 10 and 20 µg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. <b>2011</b> , 71, 2491-509	43

364	Gender differences in pharmacokinetics of maintenance dosed buprenorphine. <b>2011</b> , 118, 479-83	41
363	The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. <b>2011</b> , 119, 1-9	48
362	Efficacy of continuing medical education to reduce the risk of buprenorphine diversion. <b>2011</b> , 41, 321-9	24
361	Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. <b>2011</b> , 4, 28-41	242
360	Intersection of chronic pain treatment and opioid analgesic misuse: causes, treatments, and policy strategies. <b>2011</b> , 2, 145-62	15
359	Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. <b>2011</b> , 115, 1251-60	111
358	Early blood exchange transfusion in malignant pertussis: a case report. <b>2011</b> , 12, e107-9	32
357	Fulminant pH1N1-09 influenza-associated myocarditis in pediatric patients. <b>2011</b> , 12, e99-e101	6
356	Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone. <b>2011</b> , 12, e102-7	37
355	Inspiratory muscle training in a child with nemaline myopathy and organ transplantation. <b>2011</b> , 12, e94-8	8
354	Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients. <b>2011</b> , 30, 613-20	16
353	The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. <b>2011</b> , 106, 1460-73	55
352	Development and validation of a method for the determination of buprenorphine and norbuprenorphine in breast milk by gas chromatography-mass spectrometry. <b>2012</b> , 26, 358-62	7
351	Buprenorphine modulates methamphetamine-induced dopamine dynamics in the rat caudate nucleus. <b>2011</b> , 19, 94-101	18
350	Development and validation of a highly sensitive GC/MS method for the determination of buprenorphine and nor-buprenorphine in blood. <b>2011</b> , 54, 588-91	11
349	Transplacental transfer and metabolism of buprenorphine in preterm human placenta. <b>2011</b> , 28, 25-32	21
348	Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence. <b>2011</b> , 168, 675-9	7
347	Long-acting injectable naltrexone for the management of patients with opioid dependence. <b>2011</b> , 5, 1-9	15



346	Comorbid pain and opioid addiction: psychosocial and pharmacological treatments. <b>2011</b> , 46, 1536-52	13
345	Treatment outcome for flexible dosing buprenorphine maintenance treatment. <b>2012</b> , 38, 155-60	11
344	P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. <b>2012</b> , 343, 53-61	45
343	The science and practice of medication-assisted treatments for opioid dependence. <b>2012</b> , 47, 1026-40	24
342	Use and misuse of opioid replacement therapies: a Queensland study. <b>2012</b> , 47, 78-85	5
341	Non-analgesic effects of opioids: opioid-induced respiratory depression. <b>2012</b> , 18, 5994-6004	105
340	Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. <b>2012</b> , 40, 3215-23	47
339	Ineffective morphine treatment regimen for the control of Neonatal Abstinence Syndrome in buprenorphine- and methadone-exposed infants. <b>2012</b> , 3, 262-70	10
338	Polydrug abuse: a review of opioid and benzodiazepine combination use. <b>2012</b> , 125, 8-18	427
337	Maintenance medication for opiate addiction: the foundation of recovery. <b>2012</b> , 31, 207-25	282
336	Effect of buprenorphine dose on treatment outcome. <b>2012</b> , 31, 8-18	80
335	Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. <b>2012</b> , 120, 190-5	97
334	Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. <b>2012</b> , 220, 284-90	51
333	Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. <b>2012</b> , 107 Suppl 1, 5-27	116
332	Buprenorphine. <b>2012</b> , 514-526	
331	Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. <b>2012</b> , 10, 209-19	115
330	[Opiates, harm reduction and polysubstance abuse]. <b>2012</b> , 41, 1192-200	2
329	Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. <b>2012</b> , 5, 52-63	22

328	A history of being prescribed controlled substances and risk of drug overdose death. <b>2012</b> , 13, 87-95	168
327	Management of opioid substitution therapy during medical intervention. <b>2012</b> , 42, 242-6	8
326	Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning. <b>2013</b> , 232, 11-5	23
325	Handbook of Methadone Prescribing and Buprenorphine Therapy. <b>2013</b> ,	1
324	Mortality among clients seeking treatment for buprenorphine abuse in Finland. <b>2013</b> , 133, 391-7	10
323	Initiation of buprenorphine during incarceration and retention in treatment upon release. <b>2013</b> , 45, 222-6	46
322	Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. <b>2013</b> , 38, 2868-73	40
321	High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography-mass spectrometry. <b>2013</b> , 939, 23-31	12
320	Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity. <b>2013</b> , 56, 9156-69	22
319	Opioid receptor agonist-selective regulation of interleukin-4 in T lymphocytes. <b>2013</b> , 263, 35-42	40
318	Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans. <b>2013</b> , 131, 258-62	32
317	Buprenorphine. <b>2013</b> , 45, 939-49	30
316	Zinc and pregnancy: Marked changes on the immune response following zinc therapy for pregnant females challenged with <i>Trypanosoma cruzi</i> . <b>2013</b> , 32, 592-8	11
315	Medication-assisted treatment for opioid addiction: methadone and buprenorphine. <b>2013</b> , 21, S69-S72	28
314	Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. <b>2013</b> , 128, 71-6	74
313	Treatment of Pain and Opioid Abuse. <b>2013</b> , 39-60	3
312	Treatment of Opioid Dependence. <b>2013</b> , 61-102	3
311	Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine. <b>2013</b> , 9, 675-97	17

310	Twelve-year trend in treatment seeking for buprenorphine abuse in Finland. <b>2013</b> , 127, 207-14	21
309	Buprenorphine/naloxone sublingual tablet (Zubsolv <sup>®</sup> ): a guide to its use in the maintenance treatment of opioid dependence in the USA. <b>2013</b> , 29, 336-341	7
308	Social workers' knowledge and perceptions of effectiveness and acceptability of medication assisted treatment of substance use disorders. <b>2013</b> , 52, 43-58	14
307	Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone. <b>2013</b> , 39, 86-91	12
306	Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone. <b>2013</b> , 42, 394-403	59
305	Factors Affecting Norbuprenorphine Level in Monitoring Clinical Outcome for Buprenorphine-maintained Patients. <b>2013</b> , 12, 167-174	2
304	Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review. <b>2013</b> , 14, 1187-91	23
303	Attentional bias for nondrug reward is magnified in addiction. <b>2013</b> , 21, 499-506	89
302	Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. <b>2013</b> , 103, 917-22	187
301	Buprenorphine and buprenorphine/naloxone intoxication in children - how strong is the risk?. <b>2013</b> , 6, 63-70	6
300	Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence. <b>2014</b> , 10, 587-98	30
299	A successful switch from transdermal fentanyl to transdermal buprenorphine in a patient with neuropathic pain: a case report. <b>2014</b> , 31, 101-4	
298	Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study. <b>2014</b> , 30, 575-87	10
297	Pharmacokinetics of buprenorphine hydrochloride following intramuscular and intravenous administration to American kestrels ( <i>Falco sparverius</i> ). <b>2014</b> , 75, 711-5	12
296	Multiple mechanisms underlying the long duration of action of thienorphine, a novel partial opioid agonist for the treatment of addiction. <b>2014</b> , 20, 282-8	5
295	A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. <b>2014</b> , 8, 315-26	143
294	Combined abuse of clonidine and amitriptyline in a patient on buprenorphine maintenance treatment. <b>2014</b> , 8, 476-8	8
293	HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. <b>2014</b> , 66, 288-93	56

292	Evaluation of an improved sustained-release buprenorphine formulation for use in mice. <b>2014</b> , 75, 619-25	33
291	Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies. <b>2014</b> , 15, 2263-75	23
290	Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status. <b>2014</b> , 44, 69-82	10
289	Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. <b>2014</b> , 109, 79-87	256
288	The clinical analgesic efficacy of buprenorphine. <b>2014</b> , 39, 577-83	50
287	Oral transmucosal drug delivery for pediatric use. <b>2014</b> , 73, 50-62	78
286	Sublingual buprenorphine for acute renal colic pain management: a double-blind, randomized controlled trial. <b>2014</b> , 7, 1	29
285	A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence. <b>2014</b> , 53, 813-24	27
284	Factors contributing to the rise of buprenorphine misuse: 2008-2013. <b>2014</b> , 142, 98-104	65
283	Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. <b>2014</b> , 15, 321-37	163
282	Abuse and diversion of buprenorphine sublingual tablets and film. <b>2014</b> , 47, 27-34	68
281	The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users. <b>2014</b> , 122, 299-306	10
280	Buprenorphine-naloxone therapy in pain management. <b>2014</b> , 120, 1262-74	64
279	Cognitive performance in methadone maintenance patients: effects of time relative to dosing and maintenance dose level. <b>2014</b> , 22, 248-256	20
278	Opioid agonist treatment for pharmaceutical opioid dependent people. <b>2014</b> ,	3
277	Pharmacological Treatment of Substance Abuse Disorders. <b>2015</b> , 2331-2360	
276	Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. <b>2015</b> , 35, 670-80	29
275	Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. <b>2015</b> , 20, 784-98	25

274	The Effect of Buprenorphine on Methamphetamine Cravings. <b>2015</b> , 35, 724-7	15
273	Chronic opioid use and central sleep apnea: a review of the prevalence, mechanisms, and perioperative considerations. <b>2015</b> , 120, 1273-85	123
272	Low-dose naloxone provides an abuse-deterrent effect to buprenorphine. <b>2015</b> , 8, 791-8	5
271	Long-term administration of high doses of transdermal buprenorphine in cancer patients with severe neuropathic pain. <b>2015</b> , 8, 3621-7	6
270	New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. <b>2015</b> , 6, 1-14	34
269	Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction. <b>2015</b> , 9, 466	73
268	Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions. <b>2015</b> , 32, 2477-502	11
267	Liver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agents. <b>2015</b> , 41, 107-13	4
266	Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. <b>2015</b> , 54, 837-49	23
265	Buprenorphine decreases the CCL2-mediated chemotactic response of monocytes. <b>2015</b> , 194, 3246-58	21
264	Effects of methadone plus alcohol on cognitive performance in methadone-maintained volunteers. <b>2015</b> , 41, 251-6	8
263	Bridging waitlist delays with interim buprenorphine treatment: initial feasibility. <b>2015</b> , 51, 136-42	23
262	Evaluation of opioid modulation in major depressive disorder. <b>2015</b> , 40, 1448-55	122
261	Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. <b>2015</b> , 52, 48-57	87
260	Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands. <b>2015</b> , 23, 1701-15	13
259	Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective. <b>2015</b> , 29, 43-9	2
258	Buprenorphine and naloxone compared with methadone treatment in pregnancy. <b>2015</b> , 125, 363-368	67
257	Opioid-dependence treatment in the era of recovery: insights from a UK survey of physicians, patients and out-of-treatment opioid users. <b>2015</b> , 20, 354-362	2

256	Opioids in pregnancy and neonatal abstinence syndrome. <b>2015</b> , 39, 561-5	74
255	Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. <b>2015</b> , 24, 24-9	37
254	Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners. <b>2015</b> , 156, 133-138	14
253	Substance Abuse. <b>2015</b> ,	3
252	Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users. <b>2015</b> , 48, 70-6	22
251	Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update. <b>2015</b> , 12, 339-47	4
250	Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals. <b>2016</b> , 7, 81-6	6
249	Transdermal Buprenorphine Patches for Postoperative Pain Control in Abdominal Surgery. <b>2016</b> , 10, UC05-8	4
248	Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting. <b>2016</b> , 36, 100-3	5
247	Rhabdomyolysis With Risperidone and Escitalopram Coadministration: A Case Report. <b>2016</b> , 36, 97-8	4
246	Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder. <b>2016</b> , 36, 18-26	39
245	Dose-Dependent Flux of Buprenorphine Following Transdermal Administration in Healthy Subjects. <b>2016</b> , 56, 1263-71	8
244	The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research. <b>2017</b> , 34, 33-58	8
243	Neurocognitive, psychiatric, and substance use characteristics in opioid dependent adults. <b>2016</b> , 60, 137-43	23
242	Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers. <b>2016</b> , 162, 190-8	9
241	Treatment of Opioid Dependence With Buprenorphine/Naloxone After Liver Transplantation: Report of Two Cases. <b>2016</b> , 48, 2769-2772	7
240	Pharmacotherapy for Neonatal Abstinence Syndrome: Choosing the Right Opioid or No Opioid at All. <b>2016</b> , 35, 314-20	8
239	Continuous Perioperative Sublingual Buprenorphine. <b>2016</b> , 30, 289-293	20

238	Substance Misuse: Substitution Drugs. <b>2016</b> , 436-441	1
237	Opioid agonist treatment for pharmaceutical opioid dependent people. <b>2016</b> , CD011117	112
236	Medication-assisted treatment for substance use disorders within a national community health center research network. <b>2016</b> , 37, 625-634	16
235	Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant. <b>2016</b> , 40, 203-12	35
234	Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry. <b>2016</b> , 120, 142-52	15
233	Pain Management of Patients with Substance Abuse in the Ambulatory Setting. <b>2017</b> , 21, 9	9
232	Use of Buprenorphine in treatment of refractory depression-A review of current literature. <b>2017</b> , 26, 94-98	18
231	Probuphine <sup>®</sup> (buprenorphine implant): a promising candidate in opioid dependence. <b>2017</b> , 7, 119-134	23
230	Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study. <b>2017</b> , 23, 61-70	9
229	Buprenorphine oral lyophilisate (Espranor <sup>®</sup> ) in the substitution treatment of opioid dependence: a profile of its use. <b>2017</b> , 33, 241-248	1
228	To Stop or Not, That Is the Question: Acute Pain Management for the Patient on Chronic Buprenorphine. <b>2017</b> , 126, 1180-1186	78
227	Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians. <b>2017</b> , 13, 669-677	5
226	The galanin-3 receptor antagonist, SNAP 37889, suppresses alcohol drinking and morphine self-administration in mice. <b>2017</b> , 118, 1-12	14
225	Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System. <b>2017</b> , 129, 55-61	12
224	Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center. <b>2017</b> , 55, 12-17	18
223	Buprenorphine/Naloxone Maintenance Therapy: an Observational Retrospective Report on the Effect of Dose on 18 months Retention in an Office-Based Treatment Program. <b>2017</b> , 11, 1178221817731320	
222	2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV. <b>2017</b> , 65, e1-e37	64
221	The overlap of sleep disturbance and depression in primary care patients treated with buprenorphine. <b>2017</b> , 38, 450-454	8

220	A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration. <b>2017</b> , 83, 2458-2473	19
219	Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. <b>2017</b> , 179, 362-369	13
218	Trends in major opioid analgesic consumption in Taiwan, 2002-2014. <b>2017</b> , 116, 529-535	13
217	Value and Health Care Policy Ramifications of Opioid Use and Abuse: Can We Do Better and Now Finally Abandon Opioids?. <b>2017</b> , 32, 257-262	
216	Advances in the delivery of buprenorphine for opioid dependence. <b>2017</b> , 11, 2493-2505	38
215	Advances in the treatment of opioid use disorders. <b>2017</b> , 6, 87	9
214	What the ID Clinician Needs to Know About Buprenorphine Treatment for Opioid Use Disorder. <b>2017</b> , 4, ofw251	3
213	Buprenorphine-related complications in elderly hospitalised patients: a case series. <b>2017</b> , 45, 256-261	8
212	Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review. <b>2018</b> , 12, 170-183	28
211	The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. <b>2018</b> , 113, 1461-1476	49
210	Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study. <b>2018</b> , 235, 971-981	5
209	Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment. <b>2018</b> , 183, 127-133	8
208	Characteristics and experiences of buprenorphine-naloxone use among polysubstance users. <b>2018</b> , 44, 595-603	11
207	Comparison of intramuscular butorphanol and buprenorphine combined with dexmedetomidine for sedation in cats. <b>2018</b> , 20, 325-331	14
206	A Practical Approach to Neonatal Opiate Withdrawal Syndrome. <b>2018</b> , 35, 324-330	9
205	Buprenorphine in Neonatal Abstinence Syndrome. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 112-119	6.1 15
204	Single high-dose buprenorphine for opioid craving during withdrawal. <b>2018</b> , 19, 675	9
203	Understanding the use of diverted buprenorphine. <b>2018</b> , 193, 117-123	49



202	Voriconazole greatly increases the exposure to oral buprenorphine. <b>2018</b> , 74, 1615-1622	9
201	Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity. <b>2018</b> , 14, 306-322	33
200	Multimodal Treatment Options, Including Rotating to Buprenorphine, Within a Multidisciplinary Pain Clinic for Patients on Risky Opioid Regimens: A Quality Improvement Study. <b>2018</b> , 19, S38-S45	7
199	Frontline Science: Buprenorphine decreases CCL2-mediated migration of CD14 CD16 monocytes. <b>2018</b> , 104, 1049-1059	18
198	DARK Classics in Chemical Neuroscience: Morphine. <b>2018</b> , 9, 2395-2407	35
197	When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children. <b>2018</b> , 9, 148	21
196	Passive Addiction and Teratogenic Effects. <b>2018</b> , 1149-1189.e20	3
195	Challenges in implementing opioid agonist therapy in Lebanon: a qualitative study from a user's perspective. <b>2018</b> , 13, 14	5
194	Buprenorphine-Sustained Release Alters Hemodynamic Parameters in a Rat Burn Model. <b>2018</b> , 232, 154-159	4
193	Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years. <b>2018</b> , 836, 89-101	13
192	Buprenorphine MAT as an Imperfect Fix. <b>2018</b> , 46, 279-291	4
191	Identification, Management, and Transition of Care for Patients With Opioid Use Disorder in the Emergency Department. <b>2018</b> , 72, 420-431	55
190	Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model. <b>2018</b> , 29, 90-100	20
189	A cholecystokinin B receptor antagonist and cocaine interaction, phase I study. <b>2019</b> , 25, 136-146	3
188	Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. <b>2019</b> , 24, 576-587	73
187	Buprenorphine/naloxone induction for treatment of acute on chronic pain using a micro-dosing regimen: A case report.. <b>2019</b> , 3, 79-84	12
186	Effects of ascending buprenorphine doses on measures of experimental pain: A pilot study. <b>2019</b> , 104, 128-134	2
185	Buprenorphine treatment for opioid use disorder: recent progress. <b>2019</b> , 12, 791-803	5

184	Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol. <b>2019</b> , 39, 1023-1029	33
183	Buprenorphine in the United States: Motives for abuse, misuse, and diversion. <b>2019</b> , 104, 148-157	33
182	Factors impeding switching from methadone to buprenorphine in heroin users receiving methadone maintenance therapy - A naturalistic cohort study. <b>2019</b> , 105, 51-56	1
181	Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors. <b>2020</b> , 258, 127-145	4
180	Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review. <b>2019</b> , 20,	33
179	Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential. <b>2019</b> , 33, 1147-1154	11
178	A Biased View of $\mu$ -Opioid Receptors?. <b>2019</b> , 96, 542-549	53
177	Development of vaccines to treat opioid use disorders and reduce incidence of overdose. <b>2019</b> , 158, 107662	24
176	Maternal buprenorphine treatment during pregnancy and maternal physiology. <b>2019</b> , 201, 38-44	
175	Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?. <b>2019</b> , 40, 148-153	24
174	Non-Prescribed Buprenorphine Use Mediates the Relationship between Heroin Use and Kratom Use among a Sample of Polysubstance Users. <b>2019</b> , 51, 311-322	4
173	Methadone and buprenorphine pharmacokinetics and pharmacodynamics when coadministered with fostemsavir to opioid-dependent, human immunodeficiency virus seronegative participants. <b>2019</b> , 85, 1771-1780	7
172	Sustained-release subdermal buprenorphine implants: the future of opioid use disorder management?. <b>2019</b> , 49, 41-49	0
171	Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators. <b>2019</b> , 62, 11399-11415	3
170	Using buprenorphine to treat patients with opioid use disorder. <b>2019</b> , 32, 30-35	1
169	Medication Treatment With Methadone or Buprenorphine: Differential Reasons for Premature Discharge. <b>2019</b> , 13, 113-118	1
168	Pharmacokinetics of a Long-lasting, Highly Concentrated Buprenorphine Solution after Subcutaneous Administration in Rhesus Macaques (). <b>2019</b> , 58, 501-509	5
167	Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. <b>2019</b> , 13, 93-103	45

166	Exploring Slow Release Oral Morphine (SROM) As a Transition Bridge for Medium to High Doses of Methadone Conversion to Buprenorphine/Naloxone Sublingual: A Calgary Concept and Approach. <b>2019</b> , 10, 18-24	2
165	State-of-The-Art Treatment of Opioid Use Disorder. <b>2019</b> , 91-104	
164	Historical Review: Opiate Addiction and Opioid Receptors. <b>2019</b> , 28, 233-238	52
163	High in the sky: Iatrogenic in-flight opioid overdose caused by a dangerous emergency medical kit. <b>2019</b> , 31, 101376	2
162	Anesthesia considerations and post-operative pain management in pregnant women with chronic opioid use. <b>2019</b> , 43, 149-161	8
161	Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting. <b>2019</b> , 37, 143-150	19
160	Perioperative Management of Buprenorphine: Solving the Conundrum. <b>2019</b> , 20, 1395-1408	24
159	Treatment of Opioid Dependence. <b>2019</b> , 179-187	
158	Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. <b>2019</b> , 20, 119-128	20
157	Clinical predictors of adverse cardiovascular events for acute pediatric drug exposures. <b>2020</b> , 58, 183-189	6
156	Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. <b>2020</b> , 21, 714-723	22
155	CCR4 Antagonist (C021) Administration Diminishes Hypersensitivity and Enhances the Analgesic Potency of Morphine and Buprenorphine in a Mouse Model of Neuropathic Pain. <b>2020</b> , 11, 1241	5
154	Toxicology and the clinical laboratory. <b>2020</b> , 917-951	1
153	Retrospective analysis of heroin detoxification with buprenorphine in a psychiatric hospital in Japan. <b>2020</b> , 40, 376-382	2
152	Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder. <b>2020</b> , 14, e188-e194	5
151	Opioid and neuroHIV Comorbidity - Current and Future Perspectives. <b>2020</b> , 15, 584-627	9
150	A narrative review of buprenorphine in adult cancer pain. <b>2020</b> , 13, 1159-1167	1
149	Opioid Use and Chronic Infections: The Value of Addressing the Syndemic in Correctional Settings Via Telemedicine Guidance and Broader Use of Long-Acting Medications. <b>2020</b> , 222, S486-S493	3

148	Buprenorphine exposures in adolescents and adults: a 10-year experience of a French Poison Control Center. <b>2021</b> , 35, 764-770	2
147	Management of Opioid Use Disorder in the Emergency Department: A White Paper Prepared for the American Academy of Emergency Medicine. <b>2020</b> , 58, 522-546	14
146	A Practical Approach for the Management of the Mixed Opioid Agonist-Antagonist Buprenorphine During Acute Pain and Surgery. <b>2020</b> , 95, 1253-1267	15
145	Opioid Therapy in Infants, Children, and Adolescents. <b>2020</b> ,	0
144	Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics. <b>2021</b> , 17, 87-103	5
143	Patterns of Neonatal Co-Exposure to Gabapentin and Commonly Abused Drugs Observed in Umbilical Cord Tissue. <b>2021</b> , 45, 506-512	0
142	Methadone and Buprenorphine Maintenance Treatment of Opioid-Related Disorders. <b>2021</b> ,	1
141	Understanding ED Buprenorphine Initiation for Opioid Use Disorder: A Guide for Emergency Nurses. <b>2021</b> , 47, 139-154	2
140	Comparative evaluation of analgesic efficacy of buprenorphine transdermal patch and fentanyl patch in management of postoperative pain after arthroscopic lower limb surgery: A randomized controlled trial. <b>2021</b> , 37, 272-278	0
139	Transmucosal Buprenorphine in the Treatment of Dyspnea: Case Series and Review of the Literature. <b>2021</b> , 2, 21-24	
138	Pharmacokinetics of Single-Dose Intramuscular and Subcutaneous Injections of Buprenorphine in Common Marmosets (). <b>2021</b> , 60, 568-575	1
137	Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo. <b>2021</b> , 46, 1220-1228	1
136	The relationship between sleep and opioids in chronic pain patients. <b>2021</b> , 44, 412-420	4
135	Sublingual Buprenorphine/Naloxone and Multi-Modal Management for High-Risk Chronic Pain Patients. <b>2021</b> , 10,	0
134	Recent Advances in the Treatment of Opioid Use Disorder. <b>2021</b> , 25, 23	0
133	The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. <b>2021</b> , 41, 425-436	5
132	Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments. <b>2021</b> , 14, 1231-1249	0
131	Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review. <b>2021</b> , 16, 36	2

130	Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology. <b>2021</b> , 230, 107961	5
129	High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. <b>2021</b> , 4, e2117128	12
128	Increasing rates of buprenorphine diversion in the United States, 2002 to 2019. <b>2021</b> , 30, 1514-1519	2
127	Buprenorphine-Related Deaths in North Carolina from 2010 to 2018. <b>2021</b> , 45, 780-791	2
126	Rapid Adoption of Low-Threshold Buprenorphine Treatment at California Emergency Departments Participating in the CA Bridge Program. <b>2021</b> , 78, 759-772	8
125	Use of non-prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration. <b>2021</b> , 127, 108349	4
124	Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. <b>2021</b> , 46, 840-859	8
123	Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain: A Systematic Review. <b>2021</b> , 4, e2124152	1
122	Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database. <b>2021</b> , 4, e2123019	0
121	A practical review of buprenorphine utilization for the emergency physician in the era of decreased prescribing restrictions. <b>2021</b> , 48, 316-322	1
120	Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study. <b>2021</b> , 130, 108405	1
119	Buprenorphine X-waiver exemption - beyond the basics for the obstetrical provider. <b>2021</b> , 3, 100451	2
118	Pharmacological Treatment of Substance Abuse in Correctional Facilities: Prospects and Barriers to Expanding Access to Evidence-Based Therapy. <b>2007</b> , 385-411	3
117	Mechanism of Action of Opioids and Clinical Effects. <b>2008</b> , 85-187	2
116	Buprenorphine Pharmacodynamics and Pharmacokinetics. <b>2013</b> , 163-181	1
115	Methadone Pharmacodynamics and Pharmacokinetics. <b>2013</b> , 59-72	2
114	Drug Interactions with Benzodiazepines. <b>2004</b> , 3-88	1
113	The Development of ProNeura Technology for the Treatment of Addictions. <b>2009</b> , 689-708	2

112	Experimental Utility and Clinical Potential of Irreversible Opioid Antagonists. <b>2009</b> , 153-174	1
111	Drug Interactions with Benzodiazepines: Epidemiologic Correlates with Other CNS Depressants and In Vitro Correlates with Inhibitors and Inducers of Cytochrome P450 3A4. <b>2012</b> , 25-116	4
110	Methadone and Buprenorphine: The Place of Opiate Replacement Therapies. <b>2016</b> , 57-67	1
109	Substitutionsbehandlung der Opiatabhängigkeit. <b>2000</b> , 601-628	1
108	Substitution management in opioid dependence. <b>2003</b> , 33-60	8
107	Central Sleep Apnea Due to Drug or Substance. <b>2013</b> , 253-264	1
106	Opioids. <b>2007</b> , 635-658	2
105	Clinical Toxicology. <b>2012</b> , 1109-1188	2
104	Buprenorphine Prevalence in DUID Cases in Southwestern Virginia: Case Studies and Observations. <b>2020</b> ,	0
103	Prognostic factors in Buprenorphine- versus methadone-maintained patients. <b>1998</b> , 186, 35-43	64
102	Microinduction of Buprenorphine/Naloxone: A Review of the Literature. <b>2021</b> , 30, 305-315	12
101	Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. <b>2015</b> , 24, 24	1
100	Practical considerations for the clinical use of buprenorphine. <b>2004</b> , 2, 4-20	48
99	Buprenorphine: a unique drug with complex pharmacology. <b>2004</b> , 2, 395-402	210
98	Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis. <b>2016</b> , 14, 417-430	9
97	Minding the brain: the role of pharmacotherapy in substance-use disorder treatment. <b>2017</b> , 19, 289-297	6
96	Treatment of opioid dependence with buprenorphine: current update. <b>2017</b> , 19, 299-308	12
95	Perioperative Management of Patients on Buprenorphine and Methadone: A Narrative Review. <b>2020</b> , 37, 247-252	1

- 94 Pain Management in Pediatric Chronic Kidney Disease. **2018**, 23, 192-202 5
- 93 Opioid use disorder in pregnancy. **2019**, 9, 359-372 3
- 92 Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated. **2021**, 195, 114805 6
- 91 Pharmakologie I Illegale Drogen. **2000**, 5-12
- 90 Pharmakologie II Substitutionsmedikamente und Opioidantagonisten. **2000**, 13-20
- 89 Substitution Treatment for Opiate Dependence. **2001**, 2167-2184
- 88 Medikamentöse Schmerztherapie in der Onkologie. **2004**, 711-727
- 87 Addiction Medicine. **2006**, 559-595
- 86 Substitute Prescribing. **2007**, 17-21
- 85 The Development of Sustained-Release Naltrexone and Clinical Use in Treating Opiate Dependence. **2009**, 675-688 1
- 84 Treating heroin dependence with diamorphine (pharmaceutical heroin). **2009**, 243-267
- 83 Pharmacology of opioid agonists and antagonists. **2009**, 15-53
- 82 Methadone maintenance treatment. **2009**, 123-157
- 81 [Treatment of acute pain during drug-assisted rehabilitation]. **2010**, 130, 738-40 0
- 80 Criminal Justice System and Addiction Treatment. **2010**, 875-888
- 79 Other Drug Use. **2013**, 129-145
- 78 Buprenorphine: Side Effects and Tolerability. **2013**, 201-211 1
- 77 Methadone and Buprenorphine Prescribing in the Palliative Care Population. **2013**, 241-261

- 76 Buprenorphine Analgesia in Chronic Pain. **2013**, 109-137 ○
- 75 Buprenorphine for opioid dependence. **2013**, 3, 286-289 ○
- 74 Analgetika. **2015**, 417-651
- 73 Pregnancy and Substance Abuse. **2015**, 453-494
- 72 Analgesia for Moderate Chronic Non-Cancer Pain : Low Dose Transdermal Buprenorphine A Novel Option in Mexico. **2016**, 3, 1-6 ○
- 71 Three high doses of buprenorphine in the treatment of prolonged and severe opium dependence: a new access. **2017**, 3, 1-3
- 70 Buprenorphine—An atypical opioid: All you need to know. **2017**, 15, 402-408
- 69 Analgetika. **2018**, 447-696
- 68 Patient in Rehab and on Buprenorphine/Methadone/Naltrexone/Naloxone. **2020**, 197-211
- 67 An Observational Comparative Study to Assess the Block Characteristics of Intrathecal Buprenorphine and Clonidine When Added to Bupivacaine for Orthopaedic Lower Limb Surgeries. **2020**, 9, 1504-1508
- 66 Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study. **2020**, 32, 58-64
- 65 Prescription de tramadol chez les enfants : une bonne alternative à la codéine ? **2020**, 33, 247-256
- 64 Identifying and Treating Opioid Misuse in Pediatric Patients. **2020**, 155-171
- 63 Physiologically-Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal Syndrome. *Clinical Pharmacology and Therapeutics*, **2021**, 6.1 2
- 62 Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report. **2021**, 11, 369-372 ○
- 61 Treatment of Opioid Use Disorder Attributed to Fentanyl With High-Dose Buprenorphine: A Case Report. **2021**, 41, 83-85
- 60 Ambulatory detoxification in alcohol use disorder and opioid use disorder. **2020**, 10, 307-316
- 59 Transdermal buprenorphine in the management of persistent pain - safety aspects. **2006**, 2, 115-25 48



58	Buprenorphine abuse in India : an update. <b>1999</b> , 41, 154-9	9
57	Buprenorphine: a (relatively) new treatment for opioid dependence. <b>2005</b> , 2, 29-39	15
56	Respiratory rates and arterial blood-gas tensions in healthy rabbits given buprenorphine, butorphanol, midazolam, or their combinations. <b>2011</b> , 50, 205-11	20
55	Update on the clinical use of buprenorphine: in opioid-related disorders. <b>2012</b> , 58, 37-41	32
54	Agonist-antagonist combinations in opioid dependence: a translational approach. <b>2010</b> , 5, 17-24	2
53	Antinociceptive effects of sustained-release buprenorphine in a model of incisional pain in rats ( <i>Rattus norvegicus</i> ). <b>2014</b> , 53, 193-7	41
52	Burden and nutritional deficiencies in opiate addiction- systematic review article. <b>2014</b> , 43, 1022-32	17
51	Warnings Unheeded:The Risks of Co-Prescribing Opioids and Benzodiazepines. <b>2015</b> , 23, 1-7	1
50	Extended-release Buprenorphine, an FDA indexed Analgesic, Attenuates Mechanical Hypersensitivity in Rats ( <i>Rattus norvegicus</i> ).. <b>2021</b> ,	3
49	Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program.. <b>2021</b> , 15, 11782218211061749	2
48	Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020. <b>2021</b> , 101, 103545	0
47	Buprenorphine Microdosing for the Pain and Palliative Care Clinician.. <b>2022</b> , 25, 145-154	0
46	Transdermal Buprenorphine for Pain Management Following a Neck of Femur Fracture.. <b>2022</b> , 13, 21514593211070260	
45	Analgetika. <b>2022</b> , 511-774	
44	Buprenorphine, Polydrug Use and Deaths. <b>2022</b> , 1-20	
43	Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists.. <b>2022</b> ,	0
42	Microinduction to Buprenorphine from Methadone for Chronic Pain: Outpatient Protocol with Case Examples.. <b>2022</b> , 1-9	1
41	Opioids in the Elderly Patients with Cognitive Impairment: A Narrative Review.. <b>2022</b> , 1	0

- 40 Goofballing of Opioid and Methamphetamine: The Science Behind the Deadly Cocktail.. **2022**, 13, 859563 1
- 39 Undetected Respiratory Depression in People with Opioid Use Disorder.. **2022**, 234, 109401 0
- 38 Where Opioid Overdose Patients Live Far From Treatment: Geospatial Analysis of Underserved Populations in New York State (Preprint).
- 37 Where Opioid Overdose Patients Live Far From Treatment: Geospatial Analysis of Underserved Populations in New York State.. **2022**, 8, e32133 0
- 36 Image\_1.pdf. **2020**,
- 35 Presentation\_1.pdf. **2020**,
- 34 Patients on Buprenorphine Formulations Undergoing Surgery.. **2022**, 1 0
- 33 A Review of the Safety of Buprenorphine in Special Populations. **2022**,
- 32 Outpatient Microdose Induction with Transdermal Buprenorphine: A Case Series. **2022**, 10, 1307
- 31 The history and pharmacology of buprenorphine: New advances in cats. **2022**, 45,
- 30 Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
- 29 Severe, Nondelirium Agitation as an Underreported Characteristic of Precipitated Fentanyl Withdrawal: A Case Report. Publish Ahead of Print, 0
- 28 Bridging the Macro-micro Divide: A Qualitative Meta-synthesis on the Perspectives and Experiences of Health Care Providers on the Extramedical Use and Diversion of Buprenorphine. Publish Ahead of Print,
- 27 Do buprenorphine doses and ratios matter in medication assisted treatment adherence?. **2022**, 12, 241-246
- 26 Drug listing ~~l~~enteral and parental Guidelines for the management of acute pain in specific scenarios 2022. **2022**, 3, 42-51 0
- 25 Efficacy of 3 Buprenorphine Formulations for the Attenuation of Hypersensitivity after Plantar Incision in Immunodeficient NSG Mice. **2022**, 61, 448-456 1
- 24 Opioid agonist treatment for people who are dependent on pharmaceutical opioids. **2022**, 2022, 0
- 23 Buprenorphine reverses neurocognitive impairment in EcoHIV infected mice: A potential therapy for HIV-NCI. 13, 0

22	Opioid Use Disorder: Pernicious and Persistent. <b>2022</b> , 179, 708-714	2
21	Buprenorphine, Polydrug Use, and Deaths. <b>2022</b> , 2863-2882	0
20	Effectiveness of two extended-release buprenorphine formulations during postoperative period in neonatal rats. <b>2022</b> , 17, e0276327	0
19	Endogenous opioid systems alterations in pain and opioid use disorder. 16,	0
18	Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment.	0
17	A Review of Long-acting Parenteral Analgesics for Mice and Rats. <b>2022</b> ,	0
16	Structural Alterations of the $\mu$ -opioid Receptor Ligand Moieties of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG Toxicity.	0
15	Prospective Memory, Sustained Attention and Response Inhibition in Poly-Substance Users Stable on Methadone Maintenance Treatment. 1-9	0
14	Intrauterine and Neonatal Exposure to Opioids: Toxicological, Clinical, and Medico-Legal Issues. <b>2023</b> , 11, 62	0
13	History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. <b>2023</b> , 6, 100133	0
12	Socio-demographic Profile and Help-seeking Behaviour of Buprenorphine Abusers in Singapore. <b>2006</b> , 35, 451-456	1
11	Concomitant Use of Midazolam and Buprenorphine and its Implications Among Drug Users in Singapore. <b>2007</b> , 36, 774-777	1
10	Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002-17.	0
9	An fMRI analysis of verbal and non-verbal working memory in people with a past history of opioid dependence. 17,	0
8	Machine-learning analysis of opioid use disorder informed by MOR, DOR, KOR, NOR and ZOR-based interactome networks. <b>2023</b> , 157, 106745	0
7	Changes in Psychological Outcomes after Cessation of Full Mu Agonist Long-Term Opioid Therapy for Chronic Pain. <b>2023</b> , 12, 1354	0
6	The Use of Opioids in the Management of Chronic Pain: Synopsis of the 2022 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. <b>2023</b> , 176, 388-397	1
5	Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019. <b>2023</b> , 147, 208980	0

- 4 The Howard Street Method: A Community Pharmacy-Led Low Dose Overlap Buprenorphine Initiation Protocol for Individuals Using Fentanyl. Publish Ahead of Print, ○
- 3 Pandemic telehealth flexibilities for buprenorphine treatment: A synthesis of evidence and policy implications for expanding opioid use disorder care in the U.S. ○
- 2 Treating Adolescents With Opioid Use Disorder: A Medication-Assisted Treatment Approach. 106648072311644
- 1 ERAS Protocol Options for Perioperative Pain Management of Substance Use Disorder in the Ambulatory Surgical Setting. ○